The study compared long-term results of loop neochord replacement with leaflet resection techniques in 2134 patients undergoing minimally invasive mitral valve repair.
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Valve disease
August 12, 2020
August 1, 2020
This JANS Note is an editorial in response to a recent publication by Deharo et al comparing TAVR valve-in-valve versus redo-SAVR demonstrating improved short-term outcomes with TAVR ViV. The detail limitations of this study and provide a persuasive argument for the need of a randomized trial comparing both modalities.
July 7, 2020
The author presents a totally biological solution for aortomitral endocarditis by combining AVNeo™ (Ozaki procedure) and transaortic mitral valve patch using autologous pericardium only.
June 30, 2020
Researchers from the UK reported a novel polymeric heart valve, PoliValve, which is made entirely from styrenic block copolymers.
June 11, 2020
As TAVR is used in progressively lower-risk cohorts, management of device failure will become increasingly important. This study reports the largest series of patients receiving a surgical reoperation after transcatheter aortic valve replacement (TAVR) using the STS Adult Cardiac Surgery Database.
May 11, 2020
Interesting hypothesis in a rodent model of myxomatous degeneration.
March 22, 2020
Leanne Harling interviews John McKenna about his experience in the device industry side of cardiothoracic surgery.
March 1, 2020
A very easy-to-read editorial that digests a manuscript on the IMPROVE study.
February 26, 2020
Five year results of the PARTNER II trial demonstrated no difference in the risk of stroke or death comparing TAVR to surgical aortic valve replacement among intermediate surgical risk patients.
February 24, 2020
In 2014, Edwards Lifescience launched an ambitious philanthropic initiative called Every Heartbeat Matters (EHM) with the goal of impacting the global burden of heart valve disease through the education, screening and treatment of 1 million underserved people by 2020.